Latest Insider Transactions at Sangamo Therapeutics, Inc (SGMO)
This section provides a real-time view of insider transactions for Sangamo Therapeutics, Inc (SGMO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SANGAMO THERAPEUTICS, INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SANGAMO THERAPEUTICS, INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 25
2023
|
Rolf Andrew Ramelmeier EVP, Technical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,750
-1.01%
|
$1,750
$1.33 P/Share
|
|
May 25
2023
|
Scott B. Willoughby SVP, GEN. COUNSEL & SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
1,328
-1.05%
|
$1,328
$1.33 P/Share
|
|
May 25
2023
|
Sandy Macrae PRESIDENT, CEO AND DIRECTOR |
SELL
Payment of exercise price or tax liability
|
Direct |
10,411
-1.67%
|
$10,411
$1.33 P/Share
|
|
May 25
2023
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,328
-1.0%
|
$1,328
$1.33 P/Share
|
|
May 25
2023
|
Jason D. Fontenot SVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,029
-0.74%
|
$1,029
$1.33 P/Share
|
|
May 25
2023
|
Nathalie Dubois Stringfellow SVP-CHIEF DEVELOPMENT OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,462
-1.06%
|
$1,462
$1.33 P/Share
|
|
May 25
2023
|
David Mark Mc Clung EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,925
-0.86%
|
$1,925
$1.33 P/Share
|
|
Apr 24
2023
|
Scott B. Willoughby SVP, GEN. COUNSEL & SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
3,977
-3.05%
|
$3,977
$1.65 P/Share
|
|
Mar 25
2023
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
345
-0.26%
|
$345
$1.66 P/Share
|
|
Feb 25
2023
|
Rolf Andrew Ramelmeier EVP, Technical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
15,618
-8.27%
|
$31,236
$2.66 P/Share
|
|
Feb 25
2023
|
Scott B. Willoughby SVP, GEN. COUNSEL & SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
5,128
-3.78%
|
$10,256
$2.66 P/Share
|
|
Feb 25
2023
|
Sandy Macrae PRESIDENT, CEO AND DIRECTOR |
SELL
Payment of exercise price or tax liability
|
Direct |
54,767
-8.07%
|
$109,534
$2.66 P/Share
|
|
Feb 25
2023
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
7,030
-4.99%
|
$14,060
$2.66 P/Share
|
|
Feb 25
2023
|
Jason D. Fontenot SVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,559
-4.5%
|
$13,118
$2.66 P/Share
|
|
Feb 25
2023
|
Nathalie Dubois Stringfellow SVP-CHIEF DEVELOPMENT OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
9,834
-6.63%
|
$19,668
$2.66 P/Share
|
|
Feb 25
2023
|
David Mark Mc Clung EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,745
-4.16%
|
$19,490
$2.66 P/Share
|
|
Feb 24
2023
|
Rolf Andrew Ramelmeier EVP, Technical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+19.24%
|
-
|
|
Feb 24
2023
|
Scott B. Willoughby SVP, GEN. COUNSEL & SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
42,750
+23.95%
|
-
|
|
Feb 24
2023
|
Sandy Macrae PRESIDENT, CEO AND DIRECTOR |
BUY
Grant, award, or other acquisition
|
Direct |
157,300
+18.82%
|
-
|
|
Feb 24
2023
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
53,438
+27.52%
|
-
|
|
Feb 24
2023
|
Jason D. Fontenot SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,750
+22.66%
|
-
|
|
Feb 24
2023
|
Nathalie Dubois Stringfellow SVP-CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
53,438
+26.48%
|
-
|
|
Feb 24
2023
|
David Mark Mc Clung EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,250
+19.35%
|
-
|
|
Dec 15
2022
|
Courtney Beers |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+50.0%
|
-
|
|
Dec 15
2022
|
Margaret A Horn |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+50.0%
|
-
|
|
Aug 30
2022
|
Biogen Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
100,000
-0.42%
|
$500,000
$5.27 P/Share
|
|
Aug 29
2022
|
Biogen Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
400,000
-1.66%
|
$2,000,000
$5.33 P/Share
|
|
Aug 13
2022
|
Scott B. Willoughby SVP, GEN. COUNSEL & SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
864
-0.92%
|
$5,184
$6.33 P/Share
|
|
Jun 25
2022
|
David Mark Mc Clung EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,525
-6.15%
|
$46,100
$4.31 P/Share
|
|
Jun 11
2022
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
842
-0.96%
|
$2,526
$3.76 P/Share
|
|
Jun 03
2022
|
John Markels |
BUY
Open market or private purchase
|
Direct |
6,784
+17.28%
|
$20,352
$3.69 P/Share
|
|
Jun 01
2022
|
H Stewart Parker |
BUY
Open market or private purchase
|
Direct |
5,000
+9.31%
|
$15,000
$3.6 P/Share
|
|
Apr 29
2022
|
Scott B. Willoughby SVP, GEN. COUNSEL & SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
140
-0.15%
|
$560
$4.15 P/Share
|
|
Apr 25
2022
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
662
-0.76%
|
$2,648
$4.83 P/Share
|
|
Apr 25
2022
|
Jason D. Fontenot SVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
826
-0.79%
|
$3,304
$4.83 P/Share
|
|
Apr 24
2022
|
Scott B. Willoughby SVP, GEN. COUNSEL & SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
3,976
-4.19%
|
$15,904
$4.7 P/Share
|
|
Mar 25
2022
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
345
-0.39%
|
$1,725
$5.75 P/Share
|
|
Feb 25
2022
|
Robert Carey |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+25.93%
|
-
|
|
Feb 25
2022
|
Kenneth J. Hillan |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+25.93%
|
-
|
|
Feb 25
2022
|
John Markels |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+32.72%
|
-
|
|
Feb 25
2022
|
James R Meyers |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+25.93%
|
-
|
|
Feb 25
2022
|
H Stewart Parker |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+22.24%
|
-
|
|
Feb 25
2022
|
Saira Ramasastry Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+25.93%
|
-
|
|
Feb 25
2022
|
Karen L. Smith |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+24.65%
|
-
|
|
Feb 25
2022
|
Joseph S Zakrzewski Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+17.08%
|
-
|
|
Feb 25
2022
|
Sandy Macrae PRESIDENT, CEO AND DIRECTOR |
BUY
Grant, award, or other acquisition
|
Direct |
224,000
+30.06%
|
-
|
|
Feb 25
2022
|
Sandy Macrae PRESIDENT, CEO AND DIRECTOR |
SELL
Payment of exercise price or tax liability
|
Direct |
49,890
-14.37%
|
$249,450
$5.9 P/Share
|
|
Feb 25
2022
|
David Mark Mc Clung EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,400
+24.31%
|
-
|
|
Feb 25
2022
|
David Mark Mc Clung EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,610
-3.54%
|
$23,050
$5.9 P/Share
|
|
Feb 25
2022
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
41,000
+31.84%
|
-
|